Psoriatic Arthritis

The Pharmacy Times® Psoriatic Arthritis resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
[[thumbnail_alt_text]]
It is currently uncertain to what extent interleukin inhibitors may increase the risk of serious infections and cancer in patients being treated for rheumatic diseases.
[[thumbnail_alt_text]]
Top news of the day across the health care landscape.
[[thumbnail_alt_text]]
Treatment with secukinumab (Cosentyx, Novartis) inhibited radiographic progression in most patients with psoriatic arthritis over 2 years in a phase 3 trial.
[[thumbnail_alt_text]]
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.
[[thumbnail_alt_text]]
Study results demonstrate superior efficacy and comparable safety for tildrakizumab versus a placebo in patients with psoriatic arthritis.
[[thumbnail_alt_text]]
A study of methotrexate in patients with psoriasis found that the immunosuppressive drug was more effective in patients without psoriatic arthritis than those with the added condition.
[[thumbnail_alt_text]]
Phase 2b study results show durable responses rates and symptom improvement in patients with psoriatic arthritis.
[[thumbnail_alt_text]]
The updated label includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.
[[thumbnail_alt_text]]
The label update includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.
[[thumbnail_alt_text]]
Risankizumab shows promise as an important treatment option for people living with plaque psoriasis.